PolyPeptide announces expansion of existing credit facilities
Baar, 23 May 2025 – PolyPeptide Group AG (SIX: PPGN), a specialized, global CDMO for peptide-based active pharmaceutical ingredients, today announced that it has secured additional financing under its revolving credit facility (RCF), as well as further support from its main shareholder.
With UBS as the coordinator and agent, the bank consortium including Danske Bank and Zürcher Kantonalbank have agreed to increase the available capital commitments by EUR 40 million to EUR 151 million and extend the term of its existing revolving credit facility (RCF) to March 2028.
In parallel, Draupnir Holding B.V. has strengthened its support as the Group’s main shareholder and extended the term of the existing amounts outstanding under its unsecured short-term facility with the group.
The agreements enhance the Group’s financial flexibility, as it continues its growth journey toward doubling 2023 revenue by 2028.
Marc Augustin, CFO of PolyPeptide: “The aim of PolyPeptide’s growth strategy is to meet the strong and increasing customer demand. The financing agreements will enable PolyPeptide to take advantage of emerging opportunities, including in the metabolic and GLP-1 space.”
[…]